However, the long-term benefits and harms of universal screening have not been tested in RCTs. Observational studies demon- strate that universal screening can identify severe and in scant data universal screening is associated with changes in family lifestyle behaviors. Nonfasting lipid parame- ters are similar to fasting ones, and screening with a nonfasting non HDL-C is a reasonable approach to population screening in childhood. Although research on this topic continues, universal screen- ing may be reasonable given the substantial ben- efits of identifying severe hypercholesterolemia (see Section 4.2., Severe Hypercholesterolemia ), including FH, and possible benefits of lifestyle counseling for multifactorial dyslipidemias.S4.4.4.3-3, 4.5. Other Populations at Risk Recommendation for Other Populations at Risk Referenced studies that support the recommendation are summarized in Online Data Supplements 24 to 30. COR LOE Recommendation IIa B-NR For clinical decision-making in adults of different race/ethnicities, it is reasonable for clinicians to review race/ethnic features that can influence ASCVD risk.S4.5.1-1 so as to adjust choice of statin or intensity of Synopsis Race/ethnicity factors can influence estimations of AS- intensity of treatmentS4.5.1-1 S4.5.1-4 or even lipid drug use.S4.5.1-5,S4.5.1-6 Important examples in- clude the heightened risk of ASCVD in those who iden- tify as South Asians, the increased sensitivity to statins in those who identify as East Asians, and the increased prevalence of hypertension in blacks. An important is- sue in management of ASCVD risk in those who iden- tify as Hispanics/Latinos in the United States is the lack Table 10. Racial/Ethnic Issues in Evaluation, Risk Decisions, and Treatment of ASCVD Risk Racial/Ethnic Groupings Asian * Hispanic/Latino Blacks/African Comments Evaluation ASCVD issues informed by race/ethnicity ASCVD issues informed by race/ ethnicity ASCVD risk in people of South Asian and East Asian origin varies by country of origin; individuals from South Asia (see below) have increased ASCVD risk. 